The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

Miriam Freimer, MD, clinical professor of neurology at The Ohio State University Wexner Medical Center, reflects on how findings from the RAISE-XT trial potentially translate to real-world practice ...

The pharmaceutical giant sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused ...

The landscape of gMG treatment is rapidly evolving, said John Morren, MD, of the Cleveland Clinic. The traditional approach to managing gMG involves broad immunosuppressive therapies, but emerging ...

The chief executive of Muscular Dystrophy UK and interim chief executive of Myaware UK have shared thoughts on the rejection by the NHS in ...

Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from ...

AstraZeneca has bagged a win for its rare disease pipeline, with its Phase III trial of gefurulimab demonstrating the drug’s ...

JNJ's Innovative Medicine unit posts solid Q2 growth despite Stelara's LOE, powered by Darzalex, Tremfya, Erleada and new drugs.

COMMENT: It’s not just on maternity wards where Black women are denied pain relief or more likely to suffer poorer outcomes – ...

In the second quarter, Johnson & Johnson JNJ saw 4.6% constant currency sales growth and a 1.8% decline in adjusted diluted ...